GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (NYSE:NVO) » Definitions » E10

NVO (Novo Nordisk AS) E10 : $1.87 (As of Mar. 2025)


View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk AS E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Novo Nordisk AS's adjusted earnings per share data for the three months ended in Mar. 2025 was $0.946. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $1.87 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Novo Nordisk AS's average E10 Growth Rate was 17.10% per year. During the past 3 years, the average E10 Growth Rate was 15.80% per year. During the past 5 years, the average E10 Growth Rate was 14.20% per year. During the past 10 years, the average E10 Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Novo Nordisk AS was 27.70% per year. The lowest was 11.20% per year. And the median was 15.20% per year.

As of today (2025-07-06), Novo Nordisk AS's current stock price is $69.17. Novo Nordisk AS's E10 for the quarter that ended in Mar. 2025 was $1.87. Novo Nordisk AS's Shiller PE Ratio of today is 36.99.

During the past 13 years, the highest Shiller PE Ratio of Novo Nordisk AS was 92.94. The lowest was 25.12. And the median was 37.06.


Novo Nordisk AS E10 Historical Data

The historical data trend for Novo Nordisk AS's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS E10 Chart

Novo Nordisk AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 1.19 1.28 1.52 1.67

Novo Nordisk AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 1.58 1.76 1.67 1.87

Competitive Comparison of Novo Nordisk AS's E10

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Shiller PE Ratio falls into.


;
;

Novo Nordisk AS E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk AS's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.946/120.2000*120.2000
=0.946

Current CPI (Mar. 2025) = 120.2000.

Novo Nordisk AS Quarterly Data

per share eps CPI Adj_EPS
201506 0.243 100.300 0.291
201509 0.245 100.200 0.294
201512 0.236 99.800 0.284
201603 0.277 100.200 0.332
201606 0.296 100.600 0.354
201609 0.291 100.200 0.349
201612 0.245 100.300 0.294
201703 0.292 101.200 0.347
201706 0.303 101.200 0.360
201709 0.317 101.800 0.374
201712 0.267 101.300 0.317
201803 0.364 101.700 0.430
201806 0.334 102.300 0.392
201809 0.292 102.400 0.343
201812 0.269 102.100 0.317
201903 0.330 102.900 0.385
201906 0.305 102.900 0.356
201909 0.316 102.900 0.369
201912 0.275 102.900 0.321
202003 0.373 103.300 0.434
202006 0.342 103.200 0.398
202009 0.350 103.500 0.406
202012 0.328 103.400 0.381
202103 0.436 104.300 0.502
202106 0.426 105.000 0.488
202109 0.417 105.800 0.474
202112 0.362 106.600 0.408
202203 0.461 109.900 0.504
202206 0.416 113.600 0.440
202209 0.422 116.400 0.436
202212 0.429 115.900 0.445
202303 0.631 117.300 0.647
202306 0.629 116.400 0.650
202309 0.716 117.400 0.733
202312 0.718 116.700 0.740
202403 0.828 118.400 0.841
202406 0.648 118.500 0.657
202409 0.911 118.900 0.921
202412 0.890 118.900 0.900
202503 0.946 120.200 0.946

Add all the adjusted EPS together and divide 10 will get our e10.


Novo Nordisk AS  (NYSE:NVO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Novo Nordisk AS's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=69.17/1.87
=36.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Novo Nordisk AS was 92.94. The lowest was 25.12. And the median was 37.06.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Novo Nordisk AS E10 Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.